Cardiology 2013. Part II.

ISSN: 1579-2242 (Electronic)

0300-8932 (Linking)

DOI: 10.1016/j.recesp.2012.10.019

Accession Number: 23352558

Abstract: This article summarizes the main developments reported during the year 2012 concerning ischemic heart disease, together with the most relevant innovations in the management of acute cardiac patients. Full English text available from:www.revespcardiol.org/en.

Notes: Jimenez-Candil, Javier

Diaz-Castro, Oscar

Barrabes, Jose A

Garcia de la Villa, Bernardo

Bodi Peris, Vicente

Lopez Palop, Ramon

Fernandez-Ortiz, Antonio

Martinez-Selles, Manuel

eng

spa

Spain

2013/01/29 06:00

Rev Esp Cardiol. 2013 Mar;66(3):198-204. doi: 10.1016/j.recesp.2012.10.019. Epub 2013 Jan 23.

URL: http://www.ncbi.nlm.nih.gov/pubmed/23352558

Author Address: Servicio de Cardiologia, IBSAL-Hospital Universitario de Salamanca, Universidad de Salamanca, Salamanca, Espana. Electronic address: jimenezcandil@secardiologia.es.

 

 

Reference Type:  Journal Article

Record Number: 868Author: Jones, D. A., Choudry, F. and Mathur, A.

Year: 2013

Title: Almanac 2012: cell therapy in cardiovascular disease. the national society journals present selected research that has driven recent advances in clinical cardiology

Journal: Hellenic J Cardiol

Volume: 54

Issue: 3

Pages: 159-67

Date: May-Jun

Short Title: Almanac 2012: cell therapy in cardiovascular disease. the national society journals present selected research that has driven recent advances in clinical cardiology

Alternate Journal: Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese

ISSN: 2241-5955 (Electronic)

1109-9666 (Linking)

Accession Number: 23685652

Keywords: Almanacs as Topic

Animals

Biomedical Research

Cardiovascular Diseases/*therapy

Cell- and Tissue-Based Therapy/*methods

Humans

Regenerative Medicine

Abstract: The rapid translation from bench to bedside that has been seen in the application of regenerative medicine to cardiology has led to exciting new advances in our understanding of some of the fundamental mechanisms related to human biology. The first generation of cells used in phase l-ll trials (mainly bone marrow mononuclear cells) are now entering phase III clinical trials with the goal of producing a cell-based therapeutic that can change the outcome of cardiac disease. First generation cell therapy appears to have addressed safety concerns as well as showing “activity” in numerous published meta-analyses. With the knowledge gained to date, the field is moving towards the next generation of cells-the “engineered” cell-that have been developed to display a phenotype that will further enhance the myocardial repair/salvage process. This almanac review covers the latest basic research that may soon have application to humans as well as the results of the latest clinical trials.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205